GSK, Theravance lung drug Relvar wins European green light

LONDON (Reuters) – GlaxoSmithKline and Theravance’s new inhaled lung drug Relvar has been recommended for approval in Europe, Britain’s biggest drugmaker said on Thursday. The green light from the European Medicines Agency follows approval for the product in May in the United States, where it is known as Breo. The medicine is inhaled through a palm-sized device called Ellipta. The drug consists of a corticosteroid to reduce inflammation and a novel long-acting beta-agonist (LABA), which is designed to open the airways. While the U.S. …